Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Corvus Pharmaceuticals, Inc.

CRVS

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Last trade $10.27
Day change -$0.33 (-3.11%)
Day range $10.19 – $10.92
Volume 525,119
Market cap $894M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$894.14M
Price / earnings
—
Price / book
4.29×
Price / sales
—
EV / sales
—
EV / EBITDA
-13.01×

Profitability

Earnings per share
-$0.76
Return on assets
-28.73%
Return on equity
-30.87%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
13.38×
Quick ratio
13.38×
Cash ratio
0.97×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$47.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CRVS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.58M$3.33M$3.7M$2.28M$2.12M$2.39M$2.47M$2.13M
Research and development$17.78M$15.96M$11.18M$9.94M$8.45M$7.87M$7.45M$5.97M
Total operating expenses$21.36M$19.3M$14.88M$12.22M$10.57M$10.26M$9.92M$8.11M
Operating income-$21.36M-$19.3M-$14.88M-$12.22M-$10.57M-$10.26M-$9.92M-$8.11M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$20.34M-$17.96M-$13.09M-$13.57M-$10.16M-$8M$15.73M-$13.14M
Income taxes$0$0$0$0$0$0$0$0
Net income-$20.34M-$17.96M-$13.69M-$12.32M-$10.16M-$8M$15.19M-$12.11M
Net income attributable to common shareholders-$20.34M-$17.96M-$13.69M-$12.32M-$10.16M-$8M$15.19M-$12.11M
EBITDA-$21.27M-$19.26M-$14.85M-$12.19M-$10.54M-$10.23M-$9.9M-$8.09M
Basic earnings per share-$0.22-$0.19-$0.15-$0.15-$0.12-$0.10$0.21-$0.18
Diluted earnings per share-$0.22-$0.19-$0.15-$0.15-$0.12-$0.10-$0.13-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?

Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.

GlobeNewswire Inc.

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.

Investing.com

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Three rapid-growth stocks have significantly outperformed the broader market in early 2026. Corvus Pharmaceuticals surged 188% YTD on positive Phase 1 trial data for its atopic dermatitis drug candidate soquelitinib, with a Phase 2 trial planned for early 2026. New Era Energy & Digital jumped 114% YTD following strategic partnerships in the data center space, though it faces legal scrutiny. USA Rare Earth gained 56% YTD, supported by $1.6 billion in federal investment and strong cash position, though it remains an early-stage firm without proven profitability.

GlobeNewswire Inc.

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals successfully closed an upsized public offering of 9,085,778 shares at $22.15 per share, generating approximately $201.2 million in gross proceeds. The company plans to use the net proceeds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes.

GlobeNewswire Inc.

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals priced an upsized underwritten public offering of 7.9 million shares at $22.15 per share, raising approximately $175 million in gross proceeds. The company plans to use the funds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes. The offering is expected to close on January 23, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.